SEC Filings TLDR

ATW Master Fund V LP, ATW Partners Opportunities Management, LLC, Kerry Propper, and Antonio Ruiz-Gimenez have filed a Schedule 13G for ENDRA Life Sciences Inc. The filing indicates that ATW Master Fund V LP holds 116,024 shares of common stock, representing 9.9% of the outstanding shares. The shares are subject to a b...

Victory Capital Management Inc has filed a Schedule 13G with the SEC, disclosing an increased stake in Dole plc. As of September 30, 2025, Victory Capital Management Inc owns 4,938,971 shares of Dole plc's common stock, representing a 5.19% ownership. This marks an increase of 1,155,983 shares, or 30.56%, from their pr...

JNE Partners LLP, along with JNE Master Fund LP and Jonathan Esfandi, has acquired a 5.12% stake in Cool Co Ltd., as reported in a Schedule 13G filing with the SEC. The filing indicates that the group beneficially owns 2,708,686 shares of common stock, representing 5.12% of the outstanding shares. The shares are held f...

Victory Capital Management Inc filed a Schedule 13G with the SEC, disclosing its ownership of 2,983,086 shares of Chord Energy Corp's common stock, representing 5.47% of the total shares outstanding. The filing indicates that Victory Capital Management has sole voting power over 2,882,626 shares and sole dispositive po...

The Bank of New York Mellon Corporation has filed a Schedule 13G indicating it has acquired a 5.7% stake in Comerica Inc. The filing, dated October 28, 2025, shows that the bank and its subsidiaries beneficially own 7,291,514 shares of Comerica's common stock. The shares are held in various fiduciary capacities, and no...

Athanasios Tsiakmakis has filed a Schedule 13G with the SEC, reporting ownership of 14.36% of the common stock of C3is Inc. as of October 27, 2025. The filing indicates that Tsiakmakis beneficially owns 155,000 shares, with sole voting and dispositive power over these shares. The filing is made pursuant to Rule 13d-1(c...

The Bank of New York Mellon Corporation has filed a Schedule 13G with the SEC, disclosing its ownership of 7,291,514 shares of Comerica Inc's common stock, representing a 5.7% ownership stake. The filing indicates that these shares are held in various fiduciary capacities by The Bank of New York Mellon Corporation and ...

Victory Capital Management, Inc. has filed a Schedule 13G with the SEC, reporting a 6.06% ownership stake in Angel Oak Mortgage REIT, Inc. The filing indicates that Victory Capital Management, Inc. beneficially owns 1,440,411 shares of common stock in Angel Oak Mortgage REIT, Inc. The shares are held solely by Victory ...

This Amendment No. 12 to Schedule 13D, filed by ValueAct Capital and related entities, updates their ownership and transactions in the common stock of Insight Enterprises, Inc. As of the filing date, the reporting persons collectively own 1,666,739 shares, representing approximately 5.3% of the outstanding common stock...

TransCode Therapeutics, Inc. filed an amendment to its Schedule 13D, originally submitted on October 16, 2025. The amendment includes updates to the Contingent Value Rights (CVR) Agreement, which entitles holders of Common Stock as of October 20, 2025, to receive CVRs. These CVRs grant holders 50% of the Net Proceeds f...

This filing represents Amendment No. 1 to the Schedule 13D previously filed by Seven Fleet Master Fund LP, Seven Fleet Capital Management LP, Seven Fleet Capital Management GP LLC, and Dr. Brian Liu regarding their holdings in CG Oncology, Inc. The amendment reflects an internal restructuring into a master-feeder struc...

This filing is an amendment to the Schedule 13D for Bio-Rad Laboratories, Inc., filed by Norman D. Schwartz, Steven D. Schwartz, Blue Raven Partners, L.P., and the Alice N. Schwartz Revocable Trust. The amendment reflects changes in beneficial ownership following the death of Alice N. Schwartz, who passed away on Septe...

This filing is an amendment to the Schedule 13D for Bio-Rad Laboratories, Inc., filed by Norman D. Schwartz and the Alice N. Schwartz Revocable Trust. The amendment updates the ownership details following the death of Alice N. Schwartz on September 25, 2025. Norman D. Schwartz now holds beneficial ownership of 3,228,92...

This Amendment No. 4 to Schedule 13D, filed by Material Impact Partners II, LLC, Material Impact Fund II, L.P., Adam Sharkawy, and Carmichael Roberts, updates the reporting persons' holdings and percentage ownership in Nauticus Robotics, Inc. following several corporate events. These events include the Series B Preferr...

The filing is an amendment to Schedule 13D for MultiSensor AI Holdings, Inc., detailing significant changes in ownership and transactions involving the company's common stock. The Reporting Persons, including 325 Capital Master Fund LP and other entities, have acquired a substantial number of shares through private pla...

This Amendment No. 4 to Schedule 13D, filed by Material Impact Partners II, LLC and related entities, updates the ownership details of Nauticus Robotics, Inc. following a Series B Preferred Stock financing and a 1 for 9 reverse stock split on September 5, 2025. The amendment reflects changes in the percentage ownership...

This Amendment No. 1 to the Schedule 13D filed by Lu Zhijian with respect to AvePoint, Inc. discloses a secondary offering of Common Stock. On September 16, 2025, the Reporting Person, along with other selling security holders, entered into an underwriting agreement with AvePoint, Inc. and several underwriters. The Rep...

This Amendment No. 12 to Schedule 13D, filed by ValueAct Capital and related entities, updates the beneficial ownership of Common Stock in Insight Enterprises, Inc. The reporting persons collectively own 1,666,739 shares, representing approximately 5.3% of the outstanding Common Stock. The amendment includes details of...

This Amendment No.1 to the Schedule 13D filed by TransCode Therapeutics, Inc. on October 16, 2025, updates the disclosure regarding the Contingent Value Rights Agreement (CVR Agreement) and the Amended and Restated Certificate of Designation. The CVR Agreement, effective October 8, 2025, entitles each holder of Common ...

This filing represents Amendment No. 1 to the Schedule 13D previously filed by Seven Fleet Master Fund LP, Seven Fleet Capital Management LP, Seven Fleet Capital Management GP LLC, and Dr. Brian Liu regarding their holdings in CG Oncology, Inc. The amendment reflects an internal restructuring into a master-feeder struc...

This Amendment No. 17 to the Schedule 13D for Bioceres Crop Solutions Corp. reports a decrease in the shares beneficially owned by the Reporting Persons, Bioceres Group Limited and Bioceres LLC, from 9,432,896 to 3,189,161. This reduction is due to the settlement of certain financial obligations through payment-in-kind...

This Amendment No. 17 to the Schedule 13D filed by Bioceres Group Limited and Bioceres LLC reports a decrease in the shares beneficially owned by the Reporting Persons. The decrease is a result of the settlement of certain financial obligations through payment-in-kind made in shares relating to private transactions. As...

This filing is an amendment to the Schedule 13D for Bio-Rad Laboratories, Inc., filed by Norman D. Schwartz, Steven D. Schwartz, Blue Raven Partners, L.P., and the Alice N. Schwartz Revocable Trust. The amendment reflects changes in beneficial ownership following the death of Alice N. Schwartz on September 25, 2025. No...

This filing is an amendment to the Schedule 13D for Bio-Rad Laboratories, Inc., filed by Norman D. Schwartz and the Alice N. Schwartz Revocable Trust. The amendment updates the ownership details following the death of Alice N. Schwartz on September 25, 2025. Norman D. Schwartz now holds beneficial ownership of 3,228,92...

This Amendment No. 1 to the Schedule 13D filed by Lu Zhijian for AvePoint, Inc. details a secondary offering of Common Stock. On September 16, 2025, the selling security holders, including Lu Zhijian, entered into an underwriting agreement with Jefferies LLC, Morgan Stanley & Co. LLC, Oversea-Chinese Banking Corporatio...